Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL005
MIFTS: 55

Oral Candidiasis

Categories: Gastrointestinal diseases, Infectious diseases, Oral diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Candidiasis

About this section

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis 12 54 15 17 70
Thrush 12 73 3
Candidiasis of Mouth 12
Candidiasis, Oral 44
Oral Moniliasis 12
Equine Thrush 70
Thrush, Oral 12
Candidiasis 70
Oral Thrush 62

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:14262
ICD9CM 34 112.0
MeSH 44 D002180
NCIt 50 C28137
SNOMED-CT 67 187006006
ICD10 32 B37.9
UMLS 70 C0006840 C0006849 C1299921
Sources

Summaries for Oral Candidiasis

About this section
PubMed Health : 62 About oral thrush: Oral thrush is a condition that can be difficult to recognize at first. It is rarely dangerous and not necessarily painful, but can be very unpleasant and greatly affect your quality of life. Oral thrush is caused by types of yeast fungus called Candida that live in the mucous membranes lining your mouth. Its medical name “oral candidiasis” is taken from this fungus. Oral thrush is most often caused by a type of Candida fungus called Candida albicans. Most people have small amounts of Candida on the mucous linings of their mouth without it causing any noticeable problems. But given the right conditions, the fungus can start reproducing very quickly. This often affects people who have serious diseases, and it can also be a side effect of certain types of treatment.

MalaCards based summary : Oral Candidiasis, also known as thrush, is related to denture stomatitis and candida glabrata, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is SKAP2 (Src Kinase Associated Phosphoprotein 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs Fluticasone and Nystatin have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth. Candidiasis in the mouth and throat is also called "thrush" or oropharyngeal candidiasis. Candidiasis in the esophagus (the tube that connects the throat to the stomach) is called esophageal candidiasis or Candida esophagitis. Esophageal candidiasis is one of the most common infections in people living with HIV/AIDS

Wikipedia : 73 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Sources

Related Diseases for Oral Candidiasis

About this section

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 denture stomatitis 31.2 SKAP2 DEFB4A CXCL8
2 candida glabrata 30.9 SKAP2 HTN3
3 candidiasis 30.9 STAT1 SKAP2 SH2D1A HTN3 DEFB4A DEFB1
4 amyotrophic lateral sclerosis 3 30.3 SKAP2 CLEC7A CCR6
5 exanthem 30.2 CXCL8 CD4 CCR6
6 lymphadenitis 30.1 CXCL8 CD4 CCR6
7 osteomyelitis 30.1 STAT1 IL1A CXCL8
8 mastitis 30.1 SLPI LTF CXCL8
9 immune deficiency disease 30.0 STAT1 SLPI SH2D1A IL1A CD4 CCR6
10 bronchitis 30.0 STAT1 SLPI LTF CXCL8
11 periodontitis 30.0 IL1A DEFB4A DEFB1 CXCL8
12 chronic mucocutaneous candidiasis 30.0 STAT1 CLEC7A CD4 CCR6 CARD9
13 seborrheic dermatitis 30.0 DEFB4A CD4 CCR6
14 behcet syndrome 29.9 IRF8 IL1A CXCL8 CD4 CCR6
15 tinea pedis 29.8 DEFB4A CLEC7A CARD9
16 disease by infectious agent 29.8 DEFB4A DEFB103B CD4 CCR6
17 dermatitis 29.7 STAT1 IL1A DEFB4A CXCL8 CD4 CCR6
18 esophageal candidiasis 29.7 CLEC7A CD4 CCR6 CARD9
19 cryptococcosis 29.7 CLEC7A CD4 CCR6 CARD9
20 blepharitis 29.7 STAT1 LTF CXCL8 CD4 CCR6
21 bacterial pneumonia 29.7 SLPI DEFB4A CXCL8 CD4 CCR6
22 histoplasmosis 29.7 STAT1 CLEC7A CD4 CCR6
23 psoriasis 29.7 SLPI IL1A DEFB4A CXCL8 CD4 CCR6
24 mycobacterium tuberculosis 1 29.6 STAT1 CLEC7A CD4 CCR6
25 combined immunodeficiency 29.6 STAT1 IKBKB CXCL8 CD4 CCR6
26 salmonellosis 29.6 STAT1 DEFB4A DEFB1 CXCL8 CD4 CCR6
27 mucormycosis 29.5 CLEC7A CD4 CCR6 CARD9
28 pneumocystosis 29.5 CLEC7A CD4 CCR6 CARD9
29 vaginitis 29.5 SLPI SH2D1A IL1A DEFB4A CXCL8 CD4
30 leukemia, acute myeloid 29.4 STAT1 IRF8 CXCL8 CD4 CCR6 B2M
31 vulvovaginal candidiasis 29.3 SKAP2 DEFB4A DEFB1 CLEC7A CCR6 CARD9
32 crohn's disease 29.1 LTF IL1A DEFB4A CXCL8 CD4 CCR6
33 bacterial infectious disease 29.1 LTF IL1A DEFB4A DEFB103B DEFB1 CXCL8
34 skin disease 29.1 IL1A IKBKB DEFB4A DEFB103B CXCL8 CD4
35 systemic lupus erythematosus 29.0 STAT1 LTF IRF8 IL1A CXCL8 CD4
36 dermatophytosis 29.0 STAT1 LTF DEFB4A CLEC7A CD4 CCR6
37 fungal infectious disease 28.6 STAT1 SKAP2 DENND2B DEFB4A CXCL8 CLEC7A
38 jak3-deficient severe combined immunodeficiency 11.1
39 median rhomboid glossitis 11.1
40 immunodeficiency 32b 11.0
41 reticular dysgenesis 11.0
42 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.0
43 immunodeficiency 15a 11.0
44 stomatitis 10.5
45 leukoplakia 10.5
46 acquired immunodeficiency syndrome 10.4
47 dacryocystitis 10.4 DEFB4A DEFB1
48 acute pericementitis 10.4 DEFB4A CXCL8
49 acute inflammation of lacrimal passage 10.4 DEFB4A DEFB1
50 leukoregulin 10.4 IL1A CXCL8

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 35)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Anxiety
Bronchitis Bronchopneumonia
Chronic Pulmonary Heart Disease Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophageal Candidiasis
Esophagitis Familial Atrial Fibrillation
Glossitis Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Neutropenia
Osteoporosis Paralytic Ileus
Peripheral Vascular Disease Pharyngitis
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis
Sources

Symptoms & Phenotypes for Oral Candidiasis

About this section

UMLS symptoms related to Oral Candidiasis:


oral manifestations

GenomeRNAi Phenotypes related to Oral Candidiasis according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 DEFB4A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.72 CD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.72 CD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.72 DEFA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.72 DEFB4A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-160 9.72 CD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-165 9.72 DEFB4A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.72 IKBKB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.72 DEFA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.72 DEFA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 IKBKB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 CD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 IKBKB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.72 DEFB4A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.72 DEFA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 CD4 DEFA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.72 IKBKB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.72 IKBKB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.72 DEFA1 DEFB4A IKBKB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.72 IKBKB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 DEFA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 IKBKB

MGI Mouse Phenotypes related to Oral Candidiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 B2M CARD9 CCR6 CD4 CLEC7A IKBKB
2 immune system MP:0005387 9.44 B2M CARD9 CCR6 CD4 CLEC7A IKBKB
Sources

Drugs & Therapeutics for Oral Candidiasis

About this section

PubMed Health treatment related to Oral Candidiasis: 62

Oral thrush can be treated with antimycotics. These are available as drugs that produce either a topical (local) or a systemic (throughout the whole body) effect. Medication that acts in both ways is also an option. The type of medication that is best suited for someone with a weakened immune system will depend on their individual situation.

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Voriconazole Approved Phase 4 137234-62-9 71616
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
8
Dequalinium Approved, Investigational Phase 4 6707-58-0
9
Terconazole Approved Phase 4 67915-31-5 441383
10
Nevirapine Approved Phase 4 129618-40-2 4463
11
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
12
Zidovudine Approved Phase 4 30516-87-1 35370
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
17
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
18
Salmeterol xinafoate Phase 4 94749-08-3 56801
19 Adrenergic beta-Agonists Phase 4
20 Neurotransmitter Agents Phase 4
21 Adrenergic Agonists Phase 4
22 Fluticasone-Salmeterol Drug Combination Phase 4
23 Sympathomimetics Phase 4
24 Bronchodilator Agents Phase 4
25 Anti-Asthmatic Agents Phase 4
26 Adrenergic Agents Phase 4
27 Anti-Allergic Agents Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Cytochrome P-450 CYP3A Inhibitors Phase 4
30 Anti-Infective Agents, Local Phase 4
31 Anti-Bacterial Agents Phase 4
32 Liposomal amphotericin B Phase 4
33 Ionophores Phase 4
34 Hydrocortisone hemisuccinate Phase 4
35 Hydrocortisone 17-butyrate 21-propionate Phase 4
36 Antibiotics, Antitubercular Phase 4
37 Anti-Retroviral Agents Phase 4
38 Liver Extracts Phase 4
39 Clindamycin phosphate Phase 4
40 Clindamycin palmitate Phase 4
41 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
42
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
43
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
44
Isavuconazole Approved, Investigational Phase 3 241479-67-4
45
Metronidazole Approved Phase 3 443-48-1 4173
46
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
47
tannic acid Approved Phase 3 1401-55-4
48
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
49
Simethicone Approved Phase 3 8050-81-5
50
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
2 Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin) Unknown status NCT03906916 Phase 4 Micafungin
3 Diagnosis of Pulmonary Candidiasis Unknown status NCT00537888 Phase 4 fluconazole
4 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
5 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
6 Oral Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
7 Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
8 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
9 Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
10 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
11 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
12 Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis Completed NCT01994096 Phase 4 Caspofungin
13 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
14 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
15 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
16 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
17 CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients Completed NCT00670657 Phase 4 AmBisome
18 A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
19 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
20 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Completed NCT03723525 Phase 4
21 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
22 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients Completed NCT01734525 Phase 4 Anidulafungin
23 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
24 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
25 The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients Completed NCT01495039 Phase 4 Nystatin
26 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
27 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Recruiting NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
28 A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis. Recruiting NCT04699240 Phase 4 clotrimazole vaginal tablets;Clotrimazole vaginal tablets+ Lactobacillus
29 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
30 A Randomized Controlled Trial to Compare the Efficacy of a Medical Grade Honey Formulation (L-Mesitran®) and Fluconazol (Diflucan®) for the Treatment of Recurrent Vulvovaginal Candidiasis Not yet recruiting NCT04626258 Phase 4 Fluconazole
31 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment) Terminated NCT01982071 Phase 4 Micafungin
32 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
33 A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
34 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Unknown status NCT03473418 Phase 3 Ketoconazole;Terconazole
35 "A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ". Unknown status NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
36 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
37 Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates) Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
38 A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
39 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
40 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
41 Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients Completed NCT00002446 Phase 3 Posaconazole;Fluconazole
42 A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis Completed NCT00666185 Phase 3 Micafungin;Fluconazole
43 A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis Completed NCT02184351 Phase 3 Roxanes's clotrimazole troches;Mycelex® troches
44 A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis Completed NCT00665639 Phase 3 micafungin;caspofungin
45 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
46 Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial Completed NCT01773876 Phase 3 Micafungin;PLACEBO
47 A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults Completed NCT00635648 Phase 3 caspofungin acetate
48 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis Completed NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
49 A Single Center, Open, Parallel, Comparative, Randomized Study of Micafungin (FK463) vs Fluconazole (Diflucan) in the Treatment of Invasive Candidiasis and Candidaemia (Protocol No: MCFGCAN-0301F-TW) Completed NCT00189709 Phase 3 Micafungin;fluconazole
50 A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia Completed NCT00106288 Phase 3 Micafungin;Liposomal Amphotericin B

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Chlorhexidine
chlorhexidine gluconate
Clotrimazole
Fluconazole
Flucytosine
Itraconazole
Ketoconazole
NYSTATIN PWDR

Cochrane evidence based reviews: candidiasis, oral

Sources

Genetic Tests for Oral Candidiasis

About this section
Sources

Anatomical Context for Oral Candidiasis

About this section

MalaCards organs/tissues related to Oral Candidiasis:

40
Tongue, Skin, Liver, Bone Marrow, Pituitary, Neutrophil, Myeloid
Sources

Publications for Oral Candidiasis

About this section

Articles related to Oral Candidiasis:

(show top 50) (show all 3262)
# Title Authors PMID Year
1
Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes. 54 61
15472333 2004
2
[Development of murine experimental model for candidiasis and its application]. 54 61
15550920 2004
3
Susceptibility of Candida dubliniensis to salivary histatin 3. 54 61
12499171 2003
4
Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. 61 54
12439202 2002
5
Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. 61 54
11936455 2002
6
Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. 61 54
11506465 2001
7
Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. 61 54
11083633 2000
8
Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. 54 61
11089630 2000
9
In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. 61 54
10225911 1999
10
Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/microL. SEROCO & HEMOCO Study Group. 61 54
9839750 1998
11
Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. 54 61
7742405 1995
12
Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. 54 61
7932082 1994
13
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 61 54
1569421 1992
14
Correlates of bird collisions with buildings across three North American countries. 61
32537779 2021
15
A case-control study of oral diseases and quality of life in individuals with rheumatoid arthritis and systemic lupus erythematosus. 61
32803443 2021
16
Clinical and Immunological Features of 96 Moroccan Children with SCID Phenotype: Two Decades' Experience. 61
33411152 2021
17
Empirical tests of habitat selection theory reveal that conspecific density and patch quality, but not habitat amount, drive long-distance immigration in a wild bird. 61
33742759 2021
18
Gut microbiota in two recently diverged passerine species: evaluating the effects of species identity, habitat use and geographic distance. 61
33691625 2021
19
Validation of the SavvyCheck™ Vaginal Yeast Test for Screening Pregnant Women for Vulvovaginal Candidosis: A Prospective, Cross-Sectional Study. 61
33804805 2021
20
A mixed-method simulated patient approach to explore implicit bias in health care: A feasibility study in community pharmacy. 61
32417071 2021
21
Whole-exome sequencing of T- B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants. 61
33040328 2021
22
Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. 61
33666160 2021
23
Different classes of antibiotics given to women routinely for preventing infection at caesarean section. 61
33661539 2021
24
IJV thrombophlebitis: be wary of the occult. 61
33731404 2021
25
Oral candidiasis of COVID-19 patients: Case report and review of evidence. 61
33713390 2021
26
Comparison of Antifungal Efficacy of Zataria Multiflora and Nystatin for Treatment of Denture Stomatitis: A Randomized Clinical Trial. 61
33681424 2021
27
Efficacy of Toluidine Blue-Mediated Antimicrobial Photodynamic Therapy on Candida spp. A Systematic Review. 61
33806003 2021
28
Genetic diversity and antifungal susceptibility of Candida albicans isolates from Iranian HIV-infected patients with oral candidiasis. 61
33691787 2021
29
Candida albicans CHK1 gene from two-component system is essential for its pathogenicity in oral candidiasis. 61
33635358 2021
30
The spectrum of skin diseases in four different types of organ-transplant recipients: a comparative single-centre cohort study. 61
33648926 2021
31
[Research progress of liposome drug delivery system in stomatology]. 61
33663162 2021
32
Pharyngeal haematoma and partial airway obstruction caused by interaction between warfarin and topical miconazole gel. 61
33653857 2021
33
Prospective Evaluation of Safety of Singing on Steroids: Testing the Truth of Received Wisdom. 61
33605442 2021
34
Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). 61
33529414 2021
35
Epidemiology and evolution of novel deltacoronaviruses in birds in central China. 61
33559368 2021
36
Sex-dependent risk-taking behaviour towards different predatory stimuli in the collared flycatcher. 61
33609633 2021
37
Endemicity and land-use type influence the abundance-range-size relationship of birds on a tropical island. 61
33080048 2021
38
Benefits of the Involvement of Dentists in Managing Oral Complications Among Patients With Oral Cavity and Oropharyngeal Cancer: An Analysis of Claims Data. 61
33555929 2021
39
In vitro three-dimensional organotypic culture models of the oral mucosa. 61
33447968 2021
40
Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases. 61
33557130 2021
41
Oral candidiasis in human immunodeficiency virus-infected patients under highly active antiretroviral therapy. 61
33640178 2021
42
Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan. 61
33099791 2021
43
Candida albicans Bgl2p, Ecm33p, and Als1p proteins are involved in adhesion to saliva-coated hydroxyapatite. 61
33628397 2021
44
Immune Sensing of Candida albicans. 61
33562068 2021
45
Selection and characterization of structure-switching DNA aptamers for the salivary peptide histatin 3. 61
33387594 2021
46
[Optimization of variables in photodynamic antifungal assays against Candida species]. 61
33648798 2021
47
Dual Drug Loaded Bilayer Hydrogel Coated with Citric Acid for the Treatment of Dry Mouth Syndrome. 61
33646014 2021
48
Development and machine-learning optimization of mucoadhesive nanostructured lipid carriers loaded with fluconazole for treatment of oral candidiasis. 61
33416006 2021
49
Efficacy of antifungal drugs in the treatment of oral candidiasis: A Bayesian network meta-analysis. 61
32165010 2021
50
Positive Effects of Saliva on Oral Candidiasis: Basic Research on the Analysis of Salivary Properties. 61
33671369 2021
Sources

Variations for Oral Candidiasis

About this section
Sources

Expression for Oral Candidiasis

About this section
Search GEO for disease gene expression data for Oral Candidiasis.
Sources

Pathways for Oral Candidiasis

About this section

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 13.19 STAT1 IRF8 IL1A IKBKB CXCL8 CD4
2
Innate Immune System 65
Show member pathways
 13.17 STAT1 SLPI SH2D1A LTF IRF8 IL1A
3
CCR5 Pathway in Macrophages 63
Show member pathways
 12.73 STAT1 IKBKB CXCL8 CD4 CCR6
4
Allograft rejection 1 36
Show member pathways
 12.69 STAT1 IL1A CXCL8 CD4 B2M
5
Measles 36
Show member pathways
 12.67 STAT1 IL1A IKBKB CXCL8 B2M
6
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.53 STAT1 IL1A IKBKB CXCL8 CARD9
7
NF-kappaB Signaling 4
12.25 STAT1 SH2D1A IRF8 IKBKB CARD9 B2M
8
Toll Comparative Pathway 63
Show member pathways
 12.16 STAT1 IL1A IKBKB CXCL8
9
Tuberculosis 36
12.03 STAT1 IL1A CLEC7A CARD9
10
C-type lectin receptor signaling pathway 36
Show member pathways
 12 STAT1 IKBKB CLEC7A CARD9
11
NOD-like receptor signaling pathway 36
11.96 STAT1 IKBKB DEFB4A DEFB103B DEFA1 CXCL8
12
Bacterial infections in CF airways 23
Show member pathways
 11.95 STAT1 IKBKB DEFB4A CXCL8
13
Defensins 65
Show member pathways
 11.89 LTF HTN3 DEFB4A DEFB103B DEFB1 DEFA1
14
Yersinia infection 36
11.84 SKAP2 IKBKB CXCL8 CD4
15
AGE-RAGE signaling pathway in diabetic complications 36
11.76 STAT1 IL1A CXCL8
16
IL12-mediated signaling events 1
Show member pathways
 11.72 STAT1 IKBKB CD4 B2M
17
Staphylococcus aureus infection 36
11.6 DEFB4A DEFB103B DEFB1 DEFA1
18
Pertussis 36
11.58 IRF8 IL1A CXCL8
19
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.49 IL1A IKBKB CXCL8
Sources

GO Terms for Oral Candidiasis

About this section

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 SLPI LTF IL1A DEFB4A DEFB103B DEFB1
2 extracellular region GO:0005576 9.65 SLPI LTF IL1A HTN3 DEFB4A DEFB103B
3 specific granule lumen GO:0035580 9.43 SLPI LTF B2M
4 Golgi lumen GO:0005796 8.92 DEFB4A DEFB103B DEFB1 DEFA1

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.08 SLPI SH2D1A LTF IRF8 CLEC7A CD4
2 innate immune response GO:0045087 10.05 SLPI SH2D1A IKBKB DEFB1 CLEC7A CARD9
3 chemotaxis GO:0006935 9.89 DEFB4A DEFB1 DEFA1 CXCL8 CCR6
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 LTF IKBKB CD4 CARD9
5 cellular response to lipopolysaccharide GO:0071222 9.87 IRF8 IL1A DEFA1 CXCL8
6 defense response GO:0006952 9.85 STAT1 DEFB4A DEFB103B DEFB1 DEFA1 CXCL8
7 defense response to Gram-positive bacterium GO:0050830 9.83 DEFB4A DEFB103B DEFB1 DEFA1 CARD9
8 positive regulation of interleukin-6 production GO:0032755 9.8 IL1A CLEC7A CARD9
9 positive regulation of tumor necrosis factor production GO:0032760 9.8 IL1A CLEC7A CARD9
10 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.8 LTF DEFB4A DEFB1 DEFA1 CXCL8
11 cell chemotaxis GO:0060326 9.79 DEFB4A DEFB103B CCR6
12 interferon-gamma-mediated signaling pathway GO:0060333 9.78 STAT1 IRF8 B2M
13 humoral immune response GO:0006959 9.76 SH2D1A LTF CCR6
14 antibacterial humoral response GO:0019731 9.76 SLPI LTF DEFB1 DEFA1
15 defense response to bacterium GO:0042742 9.76 SLPI LTF IRF8 HTN3 DEFB4A DEFB103B
16 defense response to Gram-negative bacterium GO:0050829 9.73 LTF DEFB4A DEFB103B DEFB1 DEFA1 CD4
17 positive regulation of interleukin-2 production GO:0032743 9.72 IL1A CLEC7A CD4
18 killing of cells of other organism GO:0031640 9.72 LTF HTN3 DEFB4A DEFB103B DEFA1
19 innate immune response in mucosa GO:0002227 9.71 LTF DEFB1 DEFA1
20 defense response to protozoan GO:0042832 9.7 IRF8 DEFA1 CLEC7A
21 regulation of tumor necrosis factor production GO:0032680 9.63 LTF CARD9
22 response to molecule of bacterial origin GO:0002237 9.61 CXCL8 B2M
23 killing by host of symbiont cells GO:0051873 9.6 DEFB103B DEFA1
24 membrane disruption in other organism GO:0051673 9.59 LTF DEFA1
25 positive regulation of flagellated sperm motility involved in capacitation GO:0060474 9.56 DEFB1 CCR6
26 antimicrobial humoral response GO:0019730 9.43 LTF HTN3 DEFB4A DEFB103B DEFB1 DEFA1
27 immune response GO:0006955 9.32 SLPI IRF8 IL1A DEFB4A DEFB1 DEFA1

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 STAT1 SLPI SKAP2 SH2D1A LTF IRF8
2 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB4A DEFB103B DEFB1
Sources

Sources for Oral Candidiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....